{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:15Z","timestamp":1794047475088,"version":"4.8.0"},"reference-count":57,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common malignancy that develops in patients with ataxia-telangiectasia, a cancer-predisposing inherited syndrome characterized by inactivating germline ATM mutations. ATM is also frequently mutated in sporadic DLBCL. To investigate lymphomagenic mechanisms and lymphoma-specific dependencies underlying defective ATM, we applied RNA sequencing and genome-scale loss-of-function clustered regularly interspaced short palindromic repeats (CRISPR)\/Cas9 screens to systematically interrogate B-cell lymphomas arising in a novel murine model (Atm-\/-nu-\/-) with constitutional Atm loss, thymic aplasia but residual T-cell populations. Atm-\/-nu-\/- lymphomas, which phenotypically resemble either activated B-cell-like or germinal center B-cell-like DLBCL, harbor a complex karyotype, and are characterized by MYC pathway activation. In Atm-\/-nu-\/- lymphomas, we discovered nucleotide biosynthesis as a MYC-dependent cellular vulnerability that can be targeted through the synergistic nucleotide-depleting actions of mycophenolate mofetil (MMF) and the WEE1 inhibitor, adavosertib (AZD1775). The latter is mediated through a synthetically lethal interaction between RRM2 suppression and MYC dysregulation that results in replication stress overload in Atm-\/-nu-\/- lymphoma cells. Validation in cell line models of human DLBCL confirmed the broad applicability of nucleotide depletion as a therapeutic strategy for MYC-driven DLBCL independent of ATM mutation status. Our findings extend current understanding of lymphomagenic mechanisms underpinning ATM loss and highlight nucleotide metabolism as a targetable therapeutic vulnerability in MYC-driven DLBCL.<\/jats:p>","DOI":"10.3324\/haematol.2023.284404","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:37:49Z","timestamp":1717688269000},"page":"3989-4006","source":"Crossref","is-referenced-by-count":1,"title":["Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma"],"prefix":"10.3324","volume":"109","author":[{"given":"Nicholas","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tegan","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri","family":"Oldreive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Burley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sharma-Oates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sael","family":"Alatawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Rudzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Agathanggelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Bonifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep V.","family":"Forment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eanna","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant S.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Malcolm","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"69903","doi-asserted-by":"crossref","unstructured":"Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013; 122(24):3884-3891.","DOI":"10.1182\/blood-2013-05-498329"},{"key":"69904","doi-asserted-by":"crossref","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021; 384(9):842-858.","DOI":"10.1056\/NEJMra2027612"},{"key":"69905","doi-asserted-by":"crossref","unstructured":"Copie-Bergman C, Cuilliere-Dartigues P, Baia M. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study. Blood. 2015; 126(22):2466-2474.","DOI":"10.1182\/blood-2015-05-647602"},{"key":"69906","doi-asserted-by":"crossref","unstructured":"Horn H, Ziepert M, Becher C. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121(12):2253-2263.","DOI":"10.1182\/blood-2012-06-435842"},{"key":"69907","doi-asserted-by":"crossref","unstructured":"Staiger AM, Ziepert M, Horn H. Clinical impact of the cell-of-origin classification and the MYC\/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol. 2017; 35(22):2515-2526.","DOI":"10.1200\/JCO.2016.70.3660"},{"key":"69908","doi-asserted-by":"crossref","unstructured":"Scott DW, King RL, Staiger AM. High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018; 131(18):2060-2064.","DOI":"10.1182\/blood-2017-12-820605"},{"key":"69909","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Bens S, Advani R. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019; 37(35):3359-3368.","DOI":"10.1200\/JCO.19.00743"},{"key":"69910","doi-asserted-by":"crossref","unstructured":"Petrich AM, Gandhi M, Jovanovic B. Impact of induction regimen and stem cell transplantation on outcomes in doublehit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124(15):2354-2361.","DOI":"10.1182\/blood-2014-05-578963"},{"key":"69911","doi-asserted-by":"crossref","unstructured":"Reddy A, Zhang J, Davis NS. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017; 171(2):481-494.","DOI":"10.1016\/j.cell.2017.09.027"},{"key":"69912","doi-asserted-by":"crossref","unstructured":"Melchardt T, Hufnagl C, Weinstock DM. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget. 2016; 7(32):51494-51502.","DOI":"10.18632\/oncotarget.9860"},{"key":"69913","doi-asserted-by":"crossref","unstructured":"Leeksma OC, de Miranda NF, Veelken H. Germline mutations predisposing to diffuse large B-cell lymphoma. Blood Cancer J. 2017; 7(2):e532.","DOI":"10.1038\/bcj.2017.15"},{"key":"69914","doi-asserted-by":"crossref","unstructured":"Gr\u00f8nbaek K, Worm J, Ralfkiaer E, Ahrenkiel V, Hokland P, Guldberg P. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood. 2002; 100(4):1430-1437.","DOI":"10.1182\/blood-2002-02-0382"},{"key":"69915","doi-asserted-by":"crossref","unstructured":"Xu-Monette ZY, Zhang H, Zhu F. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020; 4(14):3391-3404.","DOI":"10.1182\/bloodadvances.2020001949"},{"key":"69916","doi-asserted-by":"crossref","unstructured":"Suarez F, Mahlaoui N, Canioni D. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol. 2015; 33(2):202-208.","DOI":"10.1200\/JCO.2014.56.5101"},{"key":"69917","doi-asserted-by":"crossref","unstructured":"Bakhtiar S, Salzmann-Manrique E, Donath H. The incidence and type of cancer in patients with ataxiatelangiectasia via a retrospective single-centre study. Br J Haematol. 2021; 194(5):879-887.","DOI":"10.1111\/bjh.17736"},{"key":"69918","doi-asserted-by":"crossref","unstructured":"Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016; 11(1):159.","DOI":"10.1186\/s13023-016-0543-7"},{"key":"69919","doi-asserted-by":"crossref","unstructured":"Lee JH, Paull TT. Cellular functions of the protein kinase ATM and their relevance to human disease. Nat Rev Mol Cell Biol. 2021; 22(12):796-814.","DOI":"10.1038\/s41580-021-00394-2"},{"key":"69920","doi-asserted-by":"crossref","unstructured":"Hathcock KS, Padilla-Nash HM, Camps J. ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans. Blood. 2015; 126(20):2291-2301.","DOI":"10.1182\/blood-2015-06-654749"},{"key":"69921","doi-asserted-by":"crossref","unstructured":"Li W, Xu H, Xiao T. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014; 15(12):554.","DOI":"10.1186\/s13059-014-0554-4"},{"key":"69922","doi-asserted-by":"crossref","unstructured":"Barlow C, Hirotsune S, Paylor R. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996; 86(1):159-171.","DOI":"10.1016\/S0092-8674(00)80086-0"},{"key":"69923","doi-asserted-by":"crossref","unstructured":"Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 1996; 10(19):2411-2422.","DOI":"10.1101\/gad.10.19.2411"},{"key":"69924","doi-asserted-by":"crossref","unstructured":"Chopra C, Davies G, Taylor M. Immune deficiency in Ataxia-Telangiectasia: a longitudinal study of 44 patients. Clin Exp Immunol. 2014; 176(2):275-282.","DOI":"10.1111\/cei.12262"},{"key":"69925","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.","DOI":"10.1038\/35000501"},{"key":"69926","doi-asserted-by":"crossref","unstructured":"Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003; 100(17):9991-9996.","DOI":"10.1073\/pnas.1732008100"},{"key":"69927","doi-asserted-by":"crossref","unstructured":"Pophali PA, Marinelli LM, Ketterling RP. High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer J. 2020; 10(1):5.","DOI":"10.1038\/s41408-019-0271-z"},{"key":"69928","doi-asserted-by":"crossref","unstructured":"Liyanage M, Weaver Z, Barlow C. Abnormal rearrangement within the alpha\/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood. 2000; 96(5):1940-1946.","DOI":"10.1182\/blood.V96.5.1940"},{"key":"69929","doi-asserted-by":"crossref","unstructured":"Maclean KH, Kastan MB, Cleveland JL. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol Cancer Res. 2007; 5(7):705-711.","DOI":"10.1158\/1541-7786.MCR-07-0058"},{"key":"69930","doi-asserted-by":"crossref","unstructured":"Shreeram S, Hee WK, Demidov ON. Regulation of ATM\/ p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med. 2006; 203(13):2793-2799.","DOI":"10.1084\/jem.20061563"},{"key":"69931","doi-asserted-by":"crossref","unstructured":"Pusapati RV, Rounbehler RJ, Hong S. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci U S A. 2006; 103(5):1446-1451.","DOI":"10.1073\/pnas.0507367103"},{"key":"69932","doi-asserted-by":"crossref","unstructured":"Curti L, Campaner S. MYC-induced replicative stress: a double-edged sword for cancer development and treatment. Int J Mol Sci. 2021; 22(12):6168.","DOI":"10.3390\/ijms22126168"},{"key":"69933","doi-asserted-by":"crossref","unstructured":"Dominguez-Sola D, Ying CY, Grandori C. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007; 448(7152):445-451.","DOI":"10.1038\/nature05953"},{"key":"69934","doi-asserted-by":"crossref","unstructured":"Bester AC, Roniger M, Oren YS. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011; 145(3):435-446.","DOI":"10.1016\/j.cell.2011.03.044"},{"key":"69935","doi-asserted-by":"crossref","unstructured":"Hastak K, Paul RK, Agarwal MK. DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proc Natl Acad Sci U S A. 2008; 105(17):6314-6319.","DOI":"10.1073\/pnas.0802080105"},{"key":"69936","doi-asserted-by":"crossref","unstructured":"Poli J, Tsaponina O, Crabbe L. dNTP pools determine fork progression and origin usage under replication stress. EMBO J. 2012; 31(4):883-894.","DOI":"10.1038\/emboj.2011.470"},{"key":"69937","doi-asserted-by":"crossref","unstructured":"Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014; 16(1):2-9.","DOI":"10.1038\/ncb2897"},{"key":"69938","doi-asserted-by":"crossref","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47(2-3):85-118.","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"69939","doi-asserted-by":"crossref","unstructured":"Pfister SX, Markkanen E, Jiang Y. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell. 2015; 28(5):557-568.","DOI":"10.1016\/j.ccell.2015.09.015"},{"key":"69940","doi-asserted-by":"crossref","unstructured":"Adams JM, Harris AW, Pinkert CA. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985; 318(6046):533-538.","DOI":"10.1038\/318533a0"},{"key":"69941","doi-asserted-by":"crossref","unstructured":"Ge XQ, Jackson DA, Blow JJ. Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. Genes Dev. 2007; 21(24):3331-3341.","DOI":"10.1101\/gad.457807"},{"key":"69942","doi-asserted-by":"crossref","unstructured":"Ibarra A, Schwob E, Mendez J. Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc Natl Acad Sci U S A. 2008; 105(26):8956-8961.","DOI":"10.1073\/pnas.0803978105"},{"key":"69943","doi-asserted-by":"crossref","unstructured":"Young LA, O\u2019Connor LO, de Renty C. Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress. Cancer Res. 2019; 79(14):3762-3775.","DOI":"10.1158\/0008-5472.CAN-18-2480"},{"key":"69944","doi-asserted-by":"crossref","unstructured":"Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"69945","doi-asserted-by":"crossref","unstructured":"Tsherniak A, Vazquez F, Montgomery PG. Defining a cancer dependency map. Cell. 2017; 170(3):564-576.","DOI":"10.1016\/j.cell.2017.06.010"},{"key":"69946","doi-asserted-by":"crossref","unstructured":"Lin CY, Loven J, Rahl PB. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151(1):56-67.","DOI":"10.1016\/j.cell.2012.08.026"},{"key":"69947","doi-asserted-by":"crossref","unstructured":"Macheret M, Halazonetis TD. Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress. Nature. 2018; 555(7694):112-116.","DOI":"10.1038\/nature25507"},{"key":"69948","doi-asserted-by":"crossref","unstructured":"Liu YC, Li F, Handler J. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One. 2008; 3(7):e2722.","DOI":"10.1371\/journal.pone.0002722"},{"key":"69949","doi-asserted-by":"crossref","unstructured":"Wilson WH, Young RM, Schmitz R. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-926.","DOI":"10.1038\/nm.3884"},{"key":"69950","doi-asserted-by":"crossref","unstructured":"Shaffer AL, Phelan JD, Wang JQ. Overcoming acquired epigenetic resistance to BTK inhibitors. Blood Cancer Discov. 2021; 2(6):630-647.","DOI":"10.1158\/2643-3230.BCD-21-0063"},{"key":"69951","doi-asserted-by":"crossref","unstructured":"Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell. 2014; 157(5):1088-1103.","DOI":"10.1016\/j.cell.2014.03.052"},{"key":"69952","doi-asserted-by":"crossref","unstructured":"Do K, Wilsker D, Ji J. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015; 33(30):3409-3415.","DOI":"10.1200\/JCO.2014.60.4009"},{"key":"69953","doi-asserted-by":"crossref","unstructured":"Liu JF, Xiong N, Campos SM. Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol. 2021; 39(14):1531-1539.","DOI":"10.1200\/JCO.20.03167"},{"key":"69954","doi-asserted-by":"crossref","unstructured":"Seligmann JF, Fisher DJ, Brown LC. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. J Clin Oncol. 2021; 39(33):3705-3715.","DOI":"10.1200\/JCO.21.01435"},{"key":"69955","doi-asserted-by":"crossref","unstructured":"Christian S, Merz C, Evans L. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019; 33(10):2403-2415.","DOI":"10.1038\/s41375-019-0461-5"},{"key":"69956","doi-asserted-by":"crossref","unstructured":"Sexauer AN, Alexe G, Gustafsson K. DHODH: a promising target in the treatment of T-Acute Lymphoblastic Leukemia. Blood Adv. 2023; 7(21):6685-6701.","DOI":"10.1182\/bloodadvances.2023010337"},{"key":"69957","doi-asserted-by":"crossref","unstructured":"Morin RD, Johnson NA, Severson TM. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42(2):181-185.","DOI":"10.1038\/ng.518"},{"key":"69958","doi-asserted-by":"crossref","unstructured":"Beguelin W, Popovic R, Teater M. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-692.","DOI":"10.1016\/j.ccr.2013.04.011"},{"key":"69959","doi-asserted-by":"crossref","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015; 1(6):417-425.","DOI":"10.1016\/j.cels.2015.12.004"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284404\/77120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284404\/77836","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11636\/77120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:38Z","timestamp":1794045998000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284404","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}